Bohemia, NY (PRWEB) September 19, 2012
On September 19, 2012, nonprofit organization Voices Against Brain Cancer (VABC) commented on an article suggesting that new therapies may potentially offer new hope to patients with brain tumors.
According to an article in The Augusta Chronicle by Tom Corwin, cancer patient Olivia Mitchell’s battle against her glioblastoma multiforme brain tumor may have just become more promising thanks to Dr. Olivier Rixe, neuro-oncologist and director of the experimental therapeutics program at the Medical College of the Georgia Cancer Center. Corwin goes on to state that “Dr. Rixe has been brought in to help lead the multidisciplinary neuro-oncology program at the cancer center but also to help bring in new clinical trials for tough-to-treat cancers such as glioblastoma.”
“Rixe has been in on the development of several new drugs, the latest being Zaltrap, which was approved last month by the Food and Drug Administration to treat metastatic colorectal cancer. Rixe is trying to bring to the cancer center a glioblastoma vaccine clinical trial that he participated in elsewhere,” reported Corwin.
VABC representative Clay Darrohn said, “We believe that healthcare professionals dedicated to improving the quality of life and the diagnosis of those affected by this devastating disease, like Dr. Rixe, are imperative to the battle against brain cancer. We hope that strides continue to be made in the research field and that each day leads to more and more hope for those with brain cancer and their loved ones.”
VABC has a wide variety of initiatives in place for brain cancer research, awareness and support. The grants fund cutting-edge research programs that will have a monumental impact on the diagnosis and treatment of brain cancer. VABC currently funds research at numerous esteemed institutions such as Brookhaven National Laboratory, Cleveland Clinic, Columbia, Cornell, Duke, Harvard, John Hopkins, Memorial Sloan-Kettering and Yale, just to name a few. If you are seeking press inquiries, please contact: 5W Public Relations.